{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:30:58Z","timestamp":1759336258514},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1097\/md.0000000000010669","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T18:21:26Z","timestamp":1527099686000},"page":"e10669","source":"Crossref","is-referenced-by-count":5,"title":["Clinical impact of the alpha-galactosidase A gene single nucleotide polymorphism -10C&gt;T"],"prefix":"10.1097","volume":"97","author":[{"given":"Daniel","family":"Oder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurcan","family":"\u00dc\u00e7eyler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Salinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"M\u00fcntze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Petritsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Nordbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-18-20210226","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"R2-18-20210226","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"R3-18-20210226","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"R4-18-20210226","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"R5-18-20210226","doi-asserted-by":"crossref","first-page":"e1003632","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in Fabry disease","volume":"9","author":"Lukas","year":"2013","journal-title":"PLoS Genet"},{"key":"R6-18-20210226","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10545-014-9677-8","article-title":"Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages","volume":"37","author":"Rombach","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"R7-18-20210226","doi-asserted-by":"crossref","first-page":"e010422","DOI":"10.1136\/bmjopen-2015-010422","article-title":"Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y","volume":"6","author":"Oder","year":"2016","journal-title":"BMJ Open"},{"key":"R8-18-20210226","doi-asserted-by":"crossref","first-page":"e001691","DOI":"10.1161\/CIRCGENETICS.116.001691","article-title":"alpha-Galactosidase A genotype N215S induces a specific cardiac variant of Fabry disease","volume":"10","author":"Oder","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"R9-18-20210226","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R10-18-20210226","doi-asserted-by":"crossref","first-page":"e0182379","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS ONE"},{"key":"R11-18-20210226","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2016.04.033","article-title":"Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy","volume":"118","author":"Weidemann","year":"2016","journal-title":"Am J Cardiol"},{"key":"R12-18-20210226","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13023-014-0178-5","article-title":"Cryptogenic stroke and small fiber neuropathy of unknown etiology in patients with alpha-galactosidase A -10T genotype","volume":"9","author":"Schelleckes","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"R13-18-20210226","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinbiochem.2014.09.018","article-title":"A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene","volume":"48","author":"Tuttolomondo","year":"2015","journal-title":"Clin Biochem"},{"key":"R14-18-20210226","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/339431","article-title":"Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype","volume":"70","author":"Ishii","year":"2002","journal-title":"Am J Hum Genet"},{"key":"R15-18-20210226","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13023-014-0111-y","article-title":"Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)","volume":"9","author":"Liu","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"R16-18-20210226","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement","volume":"103","author":"Guerard","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R17-18-20210226","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"R18-18-20210226","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"key":"R19-18-20210226","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/STROKEAHA.112.663708","article-title":"Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study","volume":"44","author":"Rolfs","year":"2013","journal-title":"Stroke"},{"key":"R20-18-20210226","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.amjcard.2012.08.055","article-title":"Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with Anderson\u2013Fabry disease","volume":"111","author":"Coats","year":"2013","journal-title":"Am J Cardiol"},{"key":"R21-18-20210226","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2011.06.021","article-title":"Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease","volume":"104","author":"Torralba-Cabeza","year":"2011","journal-title":"Mol Genet Metab"},{"key":"R22-18-20210226","doi-asserted-by":"crossref","first-page":"e91757","DOI":"10.1371\/journal.pone.0091757","article-title":"Continuous cardiac troponin I release in Fabry disease","volume":"9","author":"Feustel","year":"2014","journal-title":"PLoS ONE"},{"key":"R23-18-20210226","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2261-11-6","article-title":"Persistent increase in cardiac troponin I in Fabry disease: a case report","volume":"11","author":"Tanislav","year":"2011","journal-title":"BMC Cardiovasc Disord"},{"key":"R24-18-20210226","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"R25-18-20210226","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol Genet Metab"},{"key":"R26-18-20210226","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"R27-18-20210226","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ejmg.2015.10.014","article-title":"Enzymatic diagnosis of Fabry disease using a fluorometric assay on dried blood spots: an alternative methodology","volume":"58","author":"Caudron","year":"2015","journal-title":"Eur J Med Genet"},{"key":"R28-18-20210226","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R29-18-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"R30-18-20210226","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/eurheartj\/eht098","article-title":"Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease","volume":"34","author":"Kramer","year":"2013","journal-title":"Eur Heart J"},{"key":"R31-18-20210226","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am J Cardiol"},{"key":"R32-18-20210226","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2214\/ajr.149.2.351","article-title":"MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging","volume":"149","author":"Fazekas","year":"1987","journal-title":"AJR Am J Roentgenol"},{"key":"R33-18-20210226","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pain.2006.01.041","article-title":"Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values","volume":"123","author":"Rolke","year":"2006","journal-title":"Pain"},{"key":"R34-18-20210226","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.pain.2010.07.026","article-title":"Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data","volume":"151","author":"Magerl","year":"2010","journal-title":"Pain"},{"key":"R36-18-20210226","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1212\/WNL.0b013e3181e0f7b3","article-title":"Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy","volume":"74","author":"Uceyler","year":"2010","journal-title":"Neurology"},{"key":"R37-18-20210226","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1468-1331.2005.01260.x","article-title":"EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy","volume":"12","author":"Lauria","year":"2005","journal-title":"Eur J Neurol"},{"key":"R38-18-20210226","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","article-title":"Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes","volume":"3","author":"Eng","year":"1997","journal-title":"Mol Med"},{"key":"R39-18-20210226","doi-asserted-by":"crossref","first-page":"e002114","DOI":"10.1161\/JAHA.115.002839","article-title":"High-sensitivity troponin: a clinical blood biomarker for staging cardiomyopathy in Fabry disease","volume":"5","author":"Seydelmann","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R40-18-20210226","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/AJP.0000000000000041","article-title":"Characterization of pain in Fabry disease","volume":"30","author":"Uceyler","year":"2014","journal-title":"Clin J Pain"},{"key":"R41-18-20210226","doi-asserted-by":"crossref","first-page":"e0188103","DOI":"10.1371\/journal.pone.0188103","article-title":"Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease","volume":"12","author":"Koping","year":"2017","journal-title":"PLoS ONE"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000010669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:07:39Z","timestamp":1620961659000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201805250-00018"}},"subtitle":["A single-center observational study"],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":40,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000010669","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}